Pulse Biosciences, Inc.

NASDAQ:PLSE

Medical - Instruments & Supplies

Healthcare
$45.83 +3.83%

+$0.97 today

Market cap
$3.37B
Beta
1.66
P/E (TTM)
-24.0
EPS (TTM)
-$1.10
52W Low $12.56High $28.53

Volume 0.33M

Average 0.31M

PLSE Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Pulse Biosciences, Inc.NASDAQ: PLSE

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity falls 4.8% from a year ago

Total equity stood at $99.5M at the end of Q2 FY2026, down 4.8% from a year earlier and up 50.1% from the prior quarter.

Context

  • Total equity amounted to 86.1% of total assets at the end of Q2 FY2026, down 0.8 pp from a year earlier.
  • Total equity increased in 2 of the last 3 fiscal years.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -4.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$99.5M+50.1% QoQ
Last fiscal yearDec 2025
$80.66M-29.8% YoY
Year agoJun 2025
$104.49M-4.8% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.8%——
1 year-29.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
80.66M USD
Year-over-year change
-29.8%
4-year CAGR
+22.6%

Total Equity vs competitors

How PLSE compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -4.8% is the 7th highest of 11, against a peer median of +11.6%.
  • Total equity amounts to 86.1% of total assets for PLSE, versus a peer median of 77.0%.
PLSE Competitors
Total Equity for PLSE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OPKOPKO Health, Inc.Mar 2026$1.2B USD-8.2%-6.7%64.9%
DNTHDianthus Therapeutics, Inc.Jun 2026$1.17B USD+286.7%+88.5%96.6%
NKTRNektar TherapeuticsJun 2026$903.12M USD+3830.2%-37.4%82.5%
IMTXImmatics N.V.Mar 2026€456.28M EUR-15.0%+31.4%83.9%
STAASTAAR Surgical CompanyApr 2026$352.37M USD+0.7%+0.8%78.1%
NVCRNovoCure LimitedMar 2026$330.72M USD-8.6%-8.3%42.0%
KMTSKestra Medical Technologies, Ltd.Jan 2026$287.99M USD+211.7%—75.9%
BBNXBeta Bionics, Inc.Mar 2026$271.25M USD-13.5%+180.7%89.1%
ATAIAtai Beckley Inc.Jun 2026$176.44M USD+22.6%-5.8%66.6%
PLSEPulse Biosciences, Inc.Jun 2026$99.5M USD-4.8%—86.1%
LFMDLifeMD, Inc.Mar 2026$15.04M USD+3928.6%—21.4%
Peer median (excluding PLSE) —+11.6%-2.5%77.0%

Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents28.61M61.14M44.37M118.04M80.74M
Short-term Investments00000
Net Receivables61K000274K
Inventory5.82M000136K
Other Current Assets01.01M963K1.41M2.28M
Total Current Assets36.63M62.15M45.33M119.45M83.42M
Property, Plant & Equipment (Net)11.25M10.02M8.78M8.32M7.06M
Goodwill2.79M2.79M2.79M2.79M2.79M
Intangible Assets3.22M2.55M1.89M1.22M575K
Long-term Investments(3.26M)(2.73M)1.89M00
Tax Assets3.26M2.73M001.58M
Other Non-current Assets365K365K(1.52M)677K691K
Total Non-current Assets17.62M15.73M13.83M13.01M12.69M
Total Assets54.25M77.88M59.15M132.46M96.11M
Account Payables2.9M1.57M1.84M1.67M2.78M
Short-term Debt436K917K001.57M
Tax Payables00000
Deferred Revenue16K0000
Other Current Liabilities1.46M50K3.2M1.2M1.6M
Total Current Liabilities8.52M5.98M6.71M10.06M7.92M
Long-term Debt065M000
Deferred Tax Liabilities00001.58M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities10.04M74.14M8.09M7.54M7.54M
Total Liabilities18.56M80.13M14.79M17.6M15.46M
Common Stock29K37K55K66K68K
Retained Earnings(236.2M)(294.71M)(336.92M)(390.5M)(463.28M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity35.69M(2.25M)44.36M114.86M80.66M
Total Debt11.25M75.96M9.14M8.9M7.53M
Net Debt(17.36M)14.82M(35.22M)(109.14M)(73.21M)

Pulse Biosciences, Inc.

NASDAQ:PLSE

Intrinsic Alpha fair value

Locked

Current Price

$45.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.